Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeBIOTECHNOLOGYPositive Results Announced from Pilot Study in Gout Pain at the European...

Positive Results Announced from Pilot Study in Gout Pain at the European Crystal Network Workshop 2019


Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets –

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts –

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

Dyve Bioscience, a biotech drug delivery company developing novel transdermal technologies for delivery of molecules through the skin, announced positive results from a human proof-of-concept pilot study of transdermal sodium bicarbonate for reducing pain associated with an acute gout flare.

An abstract of the results of the gout study was selected for oral presentation last week at the prestigious European Crystal Network 10th workshop 2019 in Paris, and was presented by Lisa Misell, Ph.D., VP of Clinical and Medical Affairs for Dyve Bioscience. Findings of the randomized double-blinded placebo-controlled pilot study demonstrated the effectiveness of topical transdermal-delivery sodium bicarbonate for treating the pain associated with an acute gout flare.

“Our mission is to change the standard of care for people suffering from acute gout pain, by providing immediate relief through a safe transdermal technology,” said Dr. Misell. “We are pleased with the results of this study and the company is preparing to advance the treatment into the next phase of development.”

Principal investigators Smitha Reddy, M.D., Arthritis Care and Research Center, and Arthur Ray Mabaquiao, M.D., Cabrillo Center for Rheumatic Diseases, both in San Diego, evaluated outcomes of pain relief, days until resolution and improvement in range of motion. The study enrolled 24 men and women, aged 18 to 65, with history of gout. The active treatment patients received lotion containing sodium bicarbonate and menthol while the placebo group received lotion without those ingredients. Participants were told to report to clinic within 36 hours of flare onset; all were taking 0.6mg/d or were started on 0.6mg/d colchicine.

Patients in the study were directed to apply 10 mL of lotion every 4 hours, three applications a day, to the entire limb of the target joint (identified by investigator using questionnaire) and up to two other involved joints. Follow-up time points were 15 and 30 minutes, 1, 2, 4, 6, 8, 10, 12, and 14 days, with the data collected by phone.

“We are thrilled that a high percentage of patients had immediate pain relief, as early as 15 minutes after applying treatment,” said Dr. Reddy, Member of Dyve Bioscience’s Scientific Advisory Board and principal investigator. “This could prove to be a major advancement for those suffering from gout, given the current treatment options available, which can take days to provide relief.”

Gout afflicts approximately 2-4% of the US population (10M+) and can range as high as 10% in some countries.1 However, the vast majority of treatments focus on chronic management, with very few that work within the first days following an acute attack. Of those options, some are associated with risks that make them unavailable to some patients.


1. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015 Nov;11(11):649-62.



AMRA Medical’s Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development

To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy